All terms
Breakthrough Device Designation
FDA program providing expedited review for devices that treat life-threatening or irreversibly debilitating conditions.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
The Breakthrough Devices Program offers more interactive FDA communication, sprint discussions, and prioritized review for devices that provide more effective treatment or diagnosis of serious conditions and meet at least one additional criterion such as no approved alternatives. What the regulation says
The FDA's Breakthrough Devices Program, established under Section 515(d)(4) of the Federal Food, Drug, and Cosmetic Act, aims to expedite the development and review of certain medical devices and device-led combination products. This program is detailed in the FDA guidance document, "Breakthrough Devices Program Guidance for Industry and Food and Drug Administration Staff." Devices must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, and meet specific criteria such as representing a breakthrough technology, having no approved or cleared alternatives, offering significant advantages over existing alternatives, or improving patient access. The program is distinct from Emergency Use Authorizations and is a voluntary program.What this means in practice
Designation does not change the evidentiary standard for clearance or approval but typically shortens timelines and improves alignment. Breakthrough status can also support Medicare reimbursement under the TCET pathway.Examples
- A novel AI-powered diagnostic device for early detection of pancreatic cancer, a condition with limited early detection options, receives Breakthrough Device Designation.
- A new neurostimulation device designed to reduce severe, refractory epileptic seizures, where current treatments are ineffective, is granted Breakthrough Device Designation.
- A minimally invasive surgical tool that significantly reduces recovery time and complications for a life-threatening cardiac condition, compared to existing open-heart surgery, qualifies for the program.
Common pitfalls
- •One common mistake is assuming that Breakthrough Device Designation lowers the evidentiary standards for marketing authorization, which it does not.
- •Another pitfall is delaying engagement with the FDA until late in device development, missing opportunities for early feedback and program benefits.
- •Misunderstanding the criteria for designation, particularly the "no approved or cleared alternatives" clause, can lead to wasted application efforts.
- •Failing to maintain the breakthrough characteristics throughout the development process can result in loss of designation.
- •Companies sometimes incorrectly believe that breakthrough designation guarantees Medicare reimbursement, rather than merely facilitating a pathway like TCET, which still requires its own application and review.
Frequently asked questions
The primary benefit is more interactive and timely communication with the FDA, including opportunities for sprint discussions and prioritized review, which can significantly shorten the time to market.
Cross-references
Related terms
Shared paths + categoryRegulatory
De Novo Classification Request(De Novo)
Pathway to classify novel low- to moderate-risk devices that lack a predicate.
De Novo & Breakthrough Pathways · adjacentFounder & Investor Primer · adjacent
Regulatory
510(k) Premarket Notification(510(k))
FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
De Novo & Breakthrough PathwaysFounder & Investor Primer
Regulatory
Premarket Approval(PMA)
FDA's most stringent device marketing application, required for high-risk Class III devices.
De Novo & Breakthrough PathwaysFounder & Investor Primer
Reimbursement
Transitional Coverage for Emerging Technologies(TCET)
CMS pathway providing time-limited Medicare coverage for FDA-designated Breakthrough Devices.
Regulatory
Combination Product
Product comprised of two or more regulated components - e.g., drug-device, biologic-device.
De Novo & Breakthrough Pathways
Commercialization
Freedom to Operate(FTO)
Analysis of whether a product can be sold without infringing third-party IP.
Founder & Investor Primer · adjacent
Latest in MedTech
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
FDA·1European Commission·1IMDRF·1
- 1Breakthrough Devices ProgramVerifiedFDAfda.gov
- 2European Commission - Medical DevicesVerifiedEuropean Commissionhealth.ec.europa.eu
- 3IMDRF DocumentsVerifiedIMDRFimdrf.org
Inline markers like [1] jump to the matching reference above.